PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Surgery - Market size and forecast 2018-2023 • Drugs - Market size and forecast 2018-2023 • Other treatments - Market size and forecast 2018-2023 • Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • Americas - Market size and forecast 2018-2023 • EMEA - Market size and forecast 2018-2023 • APAC - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 10: MARKET TRENDS PART 11: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 12: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Ipsen Pharma • Johnson & Johnson • Novartis • Pfizer • Teva Pharmaceutical Industries PART 13: APPENDIX • Research methodology • List of abbreviations   Exhibit 01: Years in consideration Exhibit 02: Global oncology therapeutics market Exhibit 03: Segments of global oncology therapeutics market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Type - Market share 2018-2023 (%) Exhibit 19: Comparison by type Exhibit 20: Surgery - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Surgery - Year-over-year growth 2019-2023 (%) Exhibit 22: Drugs - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Drugs - Year-over-year growth 2019-2023 (%) Exhibit 24: Other treatments - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Other treatments - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by type Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: Americas - Market size and forecast 2018-2023 ($ millions) Exhibit 31: Americas - Year-over-year growth 2019-2023 (%) Exhibit 32: Top 3 countries in Americas Exhibit 33: EMEA - Market size and forecast 2018-2023 ($ millions) Exhibit 34: EMEA - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in EMEA Exhibit 36: APAC - Market size and forecast 2018-2023 ($ millions) Exhibit 37: APAC - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in APAC Exhibit 39: Key leading countries Exhibit 40: Market opportunity Exhibit 41: Decision framework Exhibit 02: Impact of drivers and challenges Exhibit 04: Vendor landscape Exhibit 05: Landscape disruption Exhibit 06: Vendors covered Exhibit 07: Vendor classification Exhibit 08: Market positioning of vendors Exhibit 09: Ipsen Pharma - Vendor overview Exhibit 10: Ipsen Pharma - Business segments Exhibit 11: Ipsen Pharma - Organizational developments Exhibit 12: Ipsen Pharma - Geographic focus Exhibit 13: Ipsen Pharma - Segment focus Exhibit 14: Ipsen Pharma - Key offerings Exhibit 15: Ipsen Pharma - Key customers Exhibit 16: Johnson & Johnson - Vendor overview Exhibit 17: Johnson & Johnson - Business segments Exhibit 18: Johnson & Johnson - Organizational developments Exhibit 19: Johnson & Johnson - Geographic focus Exhibit 20: Johnson & Johnson - Segment focus Exhibit 21: Johnson & Johnson - Key offerings Exhibit 22: Johnson & Johnson - Key customers Exhibit 23: Novartis - Vendor overview Exhibit 24: Novartis - Business segments Exhibit 25: Novartis - Organizational developments Exhibit 26: Novartis - Geographic focus Exhibit 27: Novartis - Segment focus Exhibit 28: Novartis - Key offerings Exhibit 29: Novartis - Key customers Exhibit 30: Pfizer - Vendor overview Exhibit 31: Pfizer - Business segments Exhibit 32: Pfizer - Organizational developments Exhibit 33: Pfizer - Geographic focus Exhibit 34: Pfizer - Segment focus Exhibit 35: Pfizer - Key offerings Exhibit 36: Pfizer - Key customers Exhibit 37: Teva Pharmaceutical Industries - Vendor overview Exhibit 38: Teva Pharmaceutical Industries - Business segments Exhibit 39: Teva Pharmaceutical Industries - Organizational developments Exhibit 40: Teva Pharmaceutical Industries - Geographic focus Exhibit 41: Teva Pharmaceutical Industries - Segment focus Exhibit 42: Teva Pharmaceutical Industries - Key offerings Exhibit 43: Teva Pharmaceutical Industries - Key customers Exhibit 44: Validation techniques employed for market sizing Exhibit 45: List of abbreviations  

Ipsen Pharma Johnson & Johnson Novartis Pfizer Teva Pharmaceutical Industries